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Mucopolysaccharidosis Type 1 (MPS 1)
• Lysosomal storage disorder
Ø Lysosome: a part within each cell that is responsible for breakdown and clean-up of  old or extra 
cell components
• In Edinburgh, in the early 20th century, a child presented with the first characteristics of  what would be 
MPS 1
• In 1917, Dr. Hurler noted a patient with “coarse features, an enlarged liver and spleen, clawing of  the 
hands, and bony deformities” (13)
• Treatment in the past has been only palliative care and symptom-based interventions but has since 
progressed
Background of MPS 1
Severe
• Can have life threatening effects
• Historically called Hurler syndrome
Attenuated
• Almost normal life expectancy, but still a 
significant disability
• What was historically referred to as Hurler-
Scheie and Scheie syndromes
Spectrum of MPS 1
• Categorized into 3 different diseases based on severity of  the enzyme deficiency:
- Hurler syndrome: first described in 1917, most severe with early onset symptoms (immediately 
following birth)
- Scheie syndrome: first described in 1962, least severe symptoms and a later onset
- Hurler-Scheie syndrome: somewhat in the middle on the severity scale
• Due to the similarity in the symptoms and biochemical features, the three were combined into MPS 1 in 
1972 but are still on a spectrum of  severity
• 1 in every 100,000 live births in the U.S. have the more severe form of  the disease
• 1 in every 500,000 live births in the U.S. have the less severe form of  the disease
• The disease affects males and females equally
Frequency of MPS I
• MPS 1 is an inherited, autosomal recessive disease, 
which requires two copies (one from each parent) of  
the mutated alpha-L-iduronidase (IDUA) gene to 
show symptoms
• If  both parents are carriers for the gene, there is a 25% 
chance with each pregnancy that the child could 
inherit both copies of  the mutated gene and show 
signs of  MPS 1
• It is likely that 1 out of  every 160 people are carriers 
of  this gene in all populationsDigital image retrieved April 13, 2021 from 
https://www.mps1disease.com/healthcare/about-mps1/genetics
Genetics
Genetics of autosomal recessive disorders
Digital video retrieved April 13, 2021 from 
https://www.youtube.com/watch?v=Nv6qUsKYodA 
• The lysosome is a locale for nutrient digestion in the cell, 
housing enzymes that break down larger molecules (i.e., 
complex sugars) into smaller parts so they can be used for 
either generating energy or supporting new biosynthesis
• Mutation of  the IDUA gene causes a deficiency of the 
IDUA enzyme involved in degradation of  proteoglycans, 
which act as a lubricant in the extracellular matrix
• These undigested biomolecules accumulate in the lysosome, 
causing cellular dysfunction and inflammation of  organs
Biochemical features
Digital image retrieved March 29, 2021 from https://www.news-
medical.net/life-sciences/Structure-and-Function-of-
Proteoglycans.aspx
Proteoglycans in the 
extracellular matrix 
• Those with severe MPS 1 usually show signs within the first year of  
life, while those with attenuated MPS 1 tend to show signs in late 
childhood
• Symptoms include, but not limited to, the following:
• A large head
• Coarse facial features
• A large tongue
• Enlarged vocal cords resulting in a deep, hoarse voice
• Clouding over the cornea of  the eye/vision loss
• Severe MPS 1: multiple skeletal abnormalities, referred to as dystosis
multiplex, that can be seen by x-ray analysis and a decline in intellectual 
function that is usually present by one year of  age
Symptoms

























• Blood tests are conducted as part of  the newborn screening process to analyze the 
activity of  the IDUA enzyme; an individual with MPS1 will show low IDUA enzyme 
activity
• Urine tests are used to detect if  mucopolysaccharides (proteoglycans) are at elevated 
levels
• Prenatal diagnosis can be done by amniocentesis and chorionic villus sampling
- Amniocentesis: fluid around the fetus that contains the fetus’s DNA is removed 
and analyzed for the presence of  the mutated IDUA gene 
- Chorionic villus sampling: tissues are removed from placenta to analyze DNA
• Genetic testing of  parents to test for recessive alleles
• Characteristics such as collapsed nose bridge and other skeletal malformations can 
further provide clinical evidence to diagnosis of  MPS1
Diagnosis
Urine GAG accumulation 
and cell damage
Normal MPS I






• Enzyme Replacement Therapy (ERT) is suitable for the entire spectrum of  MPS 1; used 
only when moderate-to-severe complications are present. ERT (~$200,000/patient/year) 
only increases amount of  missing enzyme with intravenous solution. 
• Allogeneic hematopoietic stem cell transplantation (HSCT) - frontline defense for 
patients <2 years of  age to permit intellectual development (the earlier the 
better); ~$150,000/patient/year
Ø Requires suitable donor
Ø Does not help to prevent osteoarticular deformities (dysostosis multiplex or scoliosis)
Ø Risks of  the procedure include infections and graft versus host disease
• Both ERT and HSCT treatments decrease symptoms but do not cure the disease
• Before newborn screening was implemented, patient diagnosis was often much later and 
therefore delayed therapy
Ø Patients with Hurler disease: typically diagnosed within 2-3 months
Ø Patients with Scheie and Hurler-Scheie can go undiagnosed for years
Therapy




• Life expectancy varies
Ø Depends on severity of  MPS 1 in individuals
• Without treatment:
Ø Hurler side of  spectrum: patients rarely live more than 10 years
Ø Hurler-Scheie: patients live until teenage years
Ø Scheie side of  spectrum: patients often live into adulthood
• When the deficient IDUA is replaced (for example, by ERT), the new enzyme can make it to the lysosome and 
resume its role in degrading proteoglycans to alleviate the MPS I symptoms
• For information, advice & support regarding inherited genetic diseases: 
https://www.metabolicsupportuk.org/ and http://www.geneticalliance.org/
• For information specifically regarding MPS: https://mpssociety.org/ and 
http://ryanfoundation.org/who-we-are/
• For information regarding using cord blood for stem cell therapy:  https://sites.duke.edu/ccbb/
Resources
1. Beck, M., Arn, P., Giugliani, R., Muenzer, J., Okuyama, T., Taylor, J., & Fallet, S. (2014). The natural history of MPS I: global perspectives from the MPS I Registry. Genetics in medicine : official journal of the American College of Medical Genetics, 16(10), 759–765.
2. Genetics and MPS 1. (2017). MPS 1. https://www.mps1disease.com/healthcare/about-mps1/genetics
3. Mucopolysaccharidosis type I | Genetic and Rare Diseases Information Center (GARD). (2016). National Institutes of Health. https://rarediseases.info.nih.gov/diseases/10335/mucopolysaccharidosis-type-i
4. Mucopolysaccharidosis type I: MedlinePlus Genetics. (n.d.). Medlineplus.gov. Retrieved October 21, 2020, from https://medlineplus.gov/genetics/condition/mucopolysaccharidosis-type-i/#inheritance
5. Marsden, D. (2017, June 23). Mucopolysaccharidoses. NORD (National Organization for Rare Disorders). https://rarediseases.org/rare-diseases/mucopolysaccharidoses/.
6. Muenzer, J. (2011). Overview of the mucopolysaccharidoses. Rheumatology, 50(suppl_5), v4-v12.
7. Genzyme Corporation. (2019). What are the signs and symptoms of MPS I? https://www.mps1disease.com/patients/about/signs-and-symptoms.
8. Bie, H., Yin, J., He, X., Kermode, A.R., Goddard-Borger, E.D., Withers, S.G., James, M.N.G. (2013). Human Iduronidase Apo Structure P21 Form. [Photograph]. Protein Data Bank. https://www.rcsb.org/structure/4MJ4.
9. National Organization for Rare Disorders. (2017). Mucopolysaccharidoses Fact Sheet. https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Mucopolysaccharidoses-Fact-Sheet.
10. Jones, S., MD, & Wynn, R., MD. (2020). UpToDate. Retrieved October 26, 2020, from https://www.uptodate.com/contents/mucopolysaccharidoses-treatment
11. ERT. (2018, March 22). Retrieved October 26, 2020, from https://mpssociety.org/learn/treatments/ert/
12. Parini, R., Deodato, F., Di Rocco, M., Lanino, E., Locatelli, F., Messina, C., . . . Scarpa, M. (2017, June 15). Open issues in Mucopolysaccharidosis type I-Hurler. Retrieved October 26, 2020, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5472858/
13. History of MPS. (2019). Retrieved November 10, 2020, from https://www.mpssociety.ca/education/history-of-mps/
14. MPS I Signs and Symptoms. (n.d.). Sanofi. http://www.sanofimedicalaffairs.com/rarediseases/index.php/mps-i/signs-and-symptoms.
15. Pan, C., Nelson, M. S., Reyes, M., Koodie, L., Brazil, J. J., Stephenson, E. J., Zhao, R. C., Peters, C., Selleck, S. B., Stringer, S. E., & Gupta, P. (2005). Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective 
biologic activity of FGF-2 on human multipotent progenitor cells. Blood, 106(6), 1956–1964. https://doi.org/10.1182/blood-2005-02-0657
16. Goetsch, A. (2016). Hurler Syndrome (MPS 1). Retrieved December 05, 2020, from https://oncofertility.msu.edu/resources/hurler-syndrome-mps-i
Works cited
Kate Gromofsky Background, frequency, and resources
Anna Tsai Genetics




Josh Marcum Biochemical features
Contributions
